Editors' ChoiceMEDICINE

Paper of note in Science Translational Medicine 9 (419)

See allHide authors and affiliations

Science Signaling  12 Dec 2017:
Vol. 10, Issue 509, eaar6876
DOI: 10.1126/scisignal.aar6876

This week’s article describes a way to potentially reduce neurodegeneration in patients with Huntington’s disease.

HUNTINGTON’S DISEASE

Defeating neurotoxicity with a repurposed drug

Dickey et al. report that agonists of the nuclear receptors RXR and PPARδ are neuroprotective in models of Huntington’s disease because they enhance oxidative metabolism and promote autophagy-mediated protein homeostasis.

Highlighted Article

    1. A. S. Dickey,
    2. D. N. Sanchez,
    3. M. Arreola,
    4. K. R. Sampat,
    5. W. Fan,
    6. N. Arbez,
    7. S. Akimov,
    8. M. J. Van Kanegan,
    9. K. Ohnishi,
    10. S. K. Gilmore-Hall,
    11. A. L. Flores,
    12. J. M. Nguyen,
    13. N. Lomas,
    14. C. L. Hsu,
    15. D. C. Lo,
    16. C. A. Ross,
    17. E. Masliah,
    18. R. M. Evans,
    19. A. R. La Spada
    , PPARδ activation by bexarotene promotes neuroprotection by restoring bioenergetic and quality control homeostasis. Sci. Transl. Med. 9, eaal2332 (2017).
    OpenUrlAbstract/FREE Full Text
View Abstract

Article Tools

  • Email

  • Alerts
  • Citation tools

  • Paper of note in Science Translational Medicine 9 (419)

    By Leslie K. Ferrarelli

    Science Signaling

    This week’s article describes a way to potentially reduce neurodegeneration in patients with Huntington’s disease.

    CiteULike logo Connotea logo del.icio.us logo Digg logo Facebook logo Google logo Mendeley logo Reddit logo Twitter logo

Stay Connected to Science Signaling

Related Content

Similar Articles in:

Citing Articles in:

Navigate This Article